Genetic Analysis of Patients With Neovascular Age-Related Macular Degeneration Responsive to Ranibizumab But Resistant to Aflibercept View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2014-2015

ABSTRACT

A cohort of patients responsive to treatment with ranibizumab but resistant to aflibercept were identified in a previously conducted retrospective study. Identified patients will have their blood drawn for genome wide sequencing. The sequencing data will be compiled and analyzed in an attempt to identify a common genetic basis for patients susceptible to ranibizumab but resistant to aflibercept. Detailed Description A cohort of patients responsive to treatment with ranibizumab but resistant to aflibercept were identified in a previously conducted retrospective study. Identified patients will have their blood drawn for genome wide sequencing. The sequencing data will be compiled and analyzed in an attempt to identify a common genetic basis for patients susceptible to ranibizumab but resistant to aflibercept. Blood samples will be drawn for genetic analysis for all patients enrolled in the study. The sample (1 tube- 6mL of blood) will be collected using - 8.5mL PAXgene Blood DNA Tubes (http://www.qiagen.com/products/catalog/sample-technologies/dna-sample- technologies/genomic-dna/paxgene-blood-dna-tubes). Samples will be stored at -80 until time for analysis. Note that some blood draws will be performed at satellite clinics and transported to main facility for storage in -80 freezer. It is the understanding of ARC PI and staff that the PAXgene Blood DNA Tubes keep samples stable at room temp for 1-2 days. However, staff will transport samples in timely fashion (room temp, on ice, dry ice, etc), to -80 freezer for storage until all samples are collected. Once all samples are collected, they will be shipped to Genentech for analysis. DNA extraction, the generation of genetic data, and subsequent analysis will be performed at Genentech or via third party. DNA will be assayed for polymorphisms through genome wide SNP chip or whole genome sequencing. The subject's genotype or haplotype will be correlated with their visual response and OCT response. More... »

URL

https://clinicaltrials.gov/show/NCT02291887

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2620", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "A cohort of patients responsive to treatment with ranibizumab but resistant to aflibercept were identified in a previously conducted retrospective study. Identified patients will have their blood drawn for genome wide sequencing. The sequencing data will be compiled and analyzed in an attempt to identify a common genetic basis for patients susceptible to ranibizumab but resistant to aflibercept.\n\nDetailed Description\nA cohort of patients responsive to treatment with ranibizumab but resistant to aflibercept were identified in a previously conducted retrospective study. Identified patients will have their blood drawn for genome wide sequencing. The sequencing data will be compiled and analyzed in an attempt to identify a common genetic basis for patients susceptible to ranibizumab but resistant to aflibercept. Blood samples will be drawn for genetic analysis for all patients enrolled in the study. The sample (1 tube- 6mL of blood) will be collected using - 8.5mL PAXgene Blood DNA Tubes (http://www.qiagen.com/products/catalog/sample-technologies/dna-sample- technologies/genomic-dna/paxgene-blood-dna-tubes). Samples will be stored at -80 until time for analysis. Note that some blood draws will be performed at satellite clinics and transported to main facility for storage in -80 freezer. It is the understanding of ARC PI and staff that the PAXgene Blood DNA Tubes keep samples stable at room temp for 1-2 days. However, staff will transport samples in timely fashion (room temp, on ice, dry ice, etc), to -80 freezer for storage until all samples are collected. Once all samples are collected, they will be shipped to Genentech for analysis. DNA extraction, the generation of genetic data, and subsequent analysis will be performed at Genentech or via third party. DNA will be assayed for polymorphisms through genome wide SNP chip or whole genome sequencing. The subject's genotype or haplotype will be correlated with their visual response and OCT response.", 
    "endDate": "2015-07-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT02291887", 
    "keywords": [
      "genetic analysis", 
      "Macular Degeneration", 
      "ranibizumab", 
      "aflibercept", 
      "cohort", 
      "patient", 
      "retrospective study", 
      "identified patient", 
      "blood", 
      "genome-wide sequencing", 
      "sequencing data", 
      "attempt", 
      "genetic basis", 
      "blood sample", 
      "sample", 
      "satellite clinic", 
      "facility", 
      "storage", 
      "freezer", 
      "PIs", 
      "staff", 
      "room", 
      "transport", 
      "timely fashion", 
      "ice", 
      "dry ice", 
      "Genentech", 
      "DNA extraction", 
      "generation", 
      "genetic data", 
      "subsequent analysis", 
      "third party", 
      "DNA", 
      "Genetic Polymorphism", 
      "genome-wide", 
      "genome sequencing", 
      "genotype", 
      "haplotype", 
      "visual response", 
      "OCT"
    ], 
    "name": "Genetic Analysis of Patients With Neovascular Age-Related Macular Degeneration Responsive to Ranibizumab But Resistant to Aflibercept", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT02291887"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:25", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00017.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.418158.1", 
        "type": "Organization"
      }
    ], 
    "startDate": "2014-12-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "https://doi.org/10.1517/13543784.15.7.779", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001958572"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0161-6420(03)00085-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004919404"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10633-005-5319-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025922621", 
          "https://doi.org/10.1007/s10633-005-5319-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm199407143310207", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032595602"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ophtha.2005.10.052", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033900346"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ophtha.2006.01.027", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036932931"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077289523", 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT02291887"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT02291887'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT02291887'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT02291887'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT02291887'


 

This table displays all metadata directly associated to this object as RDF triples.

80 TRIPLES      16 PREDICATES      62 URIs      49 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT02291887 schema:about anzsrc-for:2620
2 schema:description A cohort of patients responsive to treatment with ranibizumab but resistant to aflibercept were identified in a previously conducted retrospective study. Identified patients will have their blood drawn for genome wide sequencing. The sequencing data will be compiled and analyzed in an attempt to identify a common genetic basis for patients susceptible to ranibizumab but resistant to aflibercept. Detailed Description A cohort of patients responsive to treatment with ranibizumab but resistant to aflibercept were identified in a previously conducted retrospective study. Identified patients will have their blood drawn for genome wide sequencing. The sequencing data will be compiled and analyzed in an attempt to identify a common genetic basis for patients susceptible to ranibizumab but resistant to aflibercept. Blood samples will be drawn for genetic analysis for all patients enrolled in the study. The sample (1 tube- 6mL of blood) will be collected using - 8.5mL PAXgene Blood DNA Tubes (http://www.qiagen.com/products/catalog/sample-technologies/dna-sample- technologies/genomic-dna/paxgene-blood-dna-tubes). Samples will be stored at -80 until time for analysis. Note that some blood draws will be performed at satellite clinics and transported to main facility for storage in -80 freezer. It is the understanding of ARC PI and staff that the PAXgene Blood DNA Tubes keep samples stable at room temp for 1-2 days. However, staff will transport samples in timely fashion (room temp, on ice, dry ice, etc), to -80 freezer for storage until all samples are collected. Once all samples are collected, they will be shipped to Genentech for analysis. DNA extraction, the generation of genetic data, and subsequent analysis will be performed at Genentech or via third party. DNA will be assayed for polymorphisms through genome wide SNP chip or whole genome sequencing. The subject's genotype or haplotype will be correlated with their visual response and OCT response.
3 schema:endDate 2015-07-01T00:00:00Z
4 schema:keywords DNA
5 DNA extraction
6 Genentech
7 Genetic Polymorphism
8 Macular Degeneration
9 OCT
10 PIs
11 aflibercept
12 attempt
13 blood
14 blood sample
15 cohort
16 dry ice
17 facility
18 freezer
19 generation
20 genetic analysis
21 genetic basis
22 genetic data
23 genome sequencing
24 genome-wide
25 genome-wide sequencing
26 genotype
27 haplotype
28 ice
29 identified patient
30 patient
31 ranibizumab
32 retrospective study
33 room
34 sample
35 satellite clinic
36 sequencing data
37 staff
38 storage
39 subsequent analysis
40 third party
41 timely fashion
42 transport
43 visual response
44 schema:name Genetic Analysis of Patients With Neovascular Age-Related Macular Degeneration Responsive to Ranibizumab But Resistant to Aflibercept
45 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT02291887
46 schema:sdDatePublished 2019-03-07T15:25
47 schema:sdLicense https://scigraph.springernature.com/explorer/license/
48 schema:sdPublisher Nb05cadb1857a454f81a17f998766da1d
49 schema:sponsor https://www.grid.ac/institutes/grid.418158.1
50 schema:startDate 2014-12-01T00:00:00Z
51 schema:subjectOf sg:pub.10.1007/s10633-005-5319-7
52 https://app.dimensions.ai/details/publication/pub.1077289523
53 https://doi.org/10.1016/j.ophtha.2005.10.052
54 https://doi.org/10.1016/j.ophtha.2006.01.027
55 https://doi.org/10.1016/s0161-6420(03)00085-x
56 https://doi.org/10.1056/nejm199407143310207
57 https://doi.org/10.1517/13543784.15.7.779
58 schema:url https://clinicaltrials.gov/show/NCT02291887
59 sgo:license sg:explorer/license/
60 sgo:sdDataset clinical_trials
61 rdf:type schema:MedicalStudy
62 Nb05cadb1857a454f81a17f998766da1d schema:name Springer Nature - SN SciGraph project
63 rdf:type schema:Organization
64 anzsrc-for:2620 schema:inDefinedTermSet anzsrc-for:
65 rdf:type schema:DefinedTerm
66 sg:pub.10.1007/s10633-005-5319-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025922621
67 https://doi.org/10.1007/s10633-005-5319-7
68 rdf:type schema:CreativeWork
69 https://app.dimensions.ai/details/publication/pub.1077289523 schema:CreativeWork
70 https://doi.org/10.1016/j.ophtha.2005.10.052 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033900346
71 rdf:type schema:CreativeWork
72 https://doi.org/10.1016/j.ophtha.2006.01.027 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036932931
73 rdf:type schema:CreativeWork
74 https://doi.org/10.1016/s0161-6420(03)00085-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1004919404
75 rdf:type schema:CreativeWork
76 https://doi.org/10.1056/nejm199407143310207 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032595602
77 rdf:type schema:CreativeWork
78 https://doi.org/10.1517/13543784.15.7.779 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001958572
79 rdf:type schema:CreativeWork
80 https://www.grid.ac/institutes/grid.418158.1 schema:Organization
 




Preview window. Press ESC to close (or click here)


...